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Abstract
Increasing incidences of thyroid cancer were observed in some countries, like USA, 
UK,  France,  and  etc.  Jointpoint  regression  was  used  to  analyze  the  incidence  of 
thyroid cancer in Shanghai, China, from 1983 to 2007. The results showed there were 
both two distinct slopes, in male representing a significant APC of 2.6% from 1983 to 
2000 (P<0.001), followed by a sharply APC of 14.4% (P <0 .001), and in female 
representing a significant APC of 4.9% from 1983 to 2003 (P<0.001), followed by a 
sharply APC of 19.9% (P =0 .001). Incidence of thyroid cancer speed-up increased in 
5-8 years after the supplement of iodine, for male and female respectively, suggesting 
either the developed screening techniques or supplement of iodine might contribute to 
this speed-up increase incidence of thyroid. The predicated future burdens indicated 
that thyroid cancer is never an unusual cancer, either in the present or in the future.
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Introduction
Thyroid cancer is the most common endocrine malignancy and includes a variety of different 
histological types of neoplasia. The annual incidence of thyroid cancer varies considerably in 
different registries, with the highest incidence rates in Hawaii and Iceland.1, 2
Compared with other tumors, thyroid cancer is an uncommon cancer, accounting for 1%–2% 
of all  neoplasms.3 Over the last few decades, increasing incidence of thyroid cancer has been 
reported  in  different  countries,  including  USA,4 UK,5 France,6 Canada,7 Australia,8 Japan,9 
German,10 Italy,11 Spain,12 and some other countries.   
In this study, we evaluated the time trends of incidence of thyroid cancer in Shanghai, China, 
from 1983 to 2007; and then predicted the future burden of thyroid cancer in Shanghai, China, in 
2010, 2015 and 2010.
Methods 
Subjects
Shanghai is the largest city in China, a seaside city located at the southeast of China and with a 
population of six millions. Data on incidence of thyroid cancer and total cancer for each gender 
were obtained from official publications of Shanghai Municipal Center for Disease Control and 
Prevention and Shanghai Cancer Institute.13 The number of patients suffering from thyroid cancer, 
the proportion of thyroid cancer in the total cancer, and the age-standard rates of thyroid cancer 
and total cancer, expressed as rates/100 000 persons, were used in the trend analysis.
Statistical methods
Joinpoint regression analysis was carried out to identify points where a statistically significant 
change over time in linear slope of the trend occurred.14 In Joinpoint analysis, the best-fitting 
points where the rate changes significantly (increase or decrease) are chosen. In the final model, 
each Joinpoint indicates a statistically significant change in trend, and an annual percentage 
change (APC) is computed for each of those trends by means of generalized linear models 
assuming a Poisson distribution. Significant changes include changes in direction or in the rate of 
increase or decrease. 
The future thyroid cancer incidence rates by gender were estimated in Shanghai urban in 
2010, 2015 and 2010, using the incidences in 2007 as basement and the average APC of the recent 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
99
4.
1 
: P
os
te
d 
2 
Ju
n 
20
11
Nature Proceeding 2011
slopes or the average APC from 1983 to 2007, respectively.
 
Figure 1 Trends in the incidence of thyroid cancer and all the cancers in male and female.
(A) Number of patients with thyroid cancer in male and female, (B) Proportion of thyroid cancer  
in all the cancers, (C) Age-standardized incidence OF thyroid cancer per 100,000 in male and 
female, (D) Joinpoint regression of incidence of thyroid cancer in male, (E) Joinpoint regression  
of incidence of thyroid cancer in female, (F) Age-standardized incidence of all the cancers per 
100,000 in male and female, (G) Joinpoint regression of incidence of all the cancers in male, and  
(H) Joinpoint regression of incidence of all the cancers in the female.
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Results
The results are summarized in Figure 1. In the year 1983, there were 34 thyroid cancer cases in 
men and 102 in women in Shanghai urban. This represents 0.4% and 1.7%, respectively, of cases 
due to malignant tumours (Fig 1a, b). While in the year of 2007, there were 137 thyroid cancer 
cases in men and 536 in women (Fig 1a, b).
In the males of Shanghai, thyroid cancer incidence rates adjusted for age tripled between 1983 
and 2007, increasing from 1.0 per 100, 000 to 3.0 per 100, 000 at an annual percentage change 
(APC)  of  5.0% (95% confidence  interval  [CI]  3.9%–6.2%)  per  annum (p<0.05,  Fig  1c).  On 
Joinpoint regression, 2 distinct slopes were apparent, representing a significant APC of 2.6% from 
1983 to 2000 (P<0.001), followed by a sharply APC of 14.4% from 2000 to 2007 (P <0 .001, Fig 
1d). 
Increasing of thyroid cancer incidence rates adjusted for age in females was more than tripled, 
from 2.6 per 100, 000 to 11.6 per 100, 000 at an APC of 6.4% (95% confidence interval [CI] 
5.3%–7.4%) per annum (p<0.05,  Fig 1c).  On Joinpoint regression, also 2 distinct  slopes were 
apparent, representing a significant APC of 4.9% from 1983 to 2003 (P<0.001), followed by a 
sharply APC of 19.9% from 2003 to 2007 (P =0 .001, Fig 1e).
Age-standard incidence of the total cancers in the males were slightly decreased from 244.4 
per 100, 000 to 207.9 per 100, 000 at an APC of -0.7 % (95% confidence interval [CI] -1.0%~-
0.4%) per annum (p<0.001, Fig 1f, g); while that in the females slight increased from 151.6 per  
100, 000 to 166.4 per 100, 000 at an APC of 0.8 % (95% confidence interval [CI] 0.6%~-1.1%) 
per annum (p<0.001, Fig 1f, h).
The predicted age-standard incidences of thyroid cancer were summarized in table 1. If the  
incidence of thyroid cancer increase at the average APC of last slope in female (2003 to 2007), the 
incidence of thyroid cancer would reach at  49.5 per 100, 000 in 2015, beyond the incidence of 
breast cancer (31.2, ranked 1st in 2007 of all cancers13).
Discussion
Recently, increasing incidence of thyroid cancer is a global trend. For example, in USA, the 
age-adjusted incidence rate (2000 USA population) increased from 3.6 per 100 000 in 1973 to 8.7 
per 100 000;4 and in UK, the age-standardised incidence (European) have increased from 1.8 to 
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3.1 per 100,000 population between 1993 and 2007, especially there has been a larger increase in 
Table 1 The future burden of thyroid cancer incidence by gender in Shanghai urban in 2010, 2015 
and 2010.
Gender The predicted age-standard incidence of 
thyroid cancer (%, using the average APC 
of the last slopes)
The predicted age-standard incidence of 
thyroid cancer (%, using the average APC 
from 1983 to 2007)
2010 2015 2020 2010 2015 2020
male 4.5 8.8 17.2 3.5 4.4 5.7
female 20.0 49.5 122.8 14.0 19.1 26.0
female, from 2.4 to 4.5 per 100,000 population.5 In the present,  age-standardised incidence of 
thyroid cancer in Shanghai increased from 1.0 to 3.0 per 100, 000 population and 2.6 to 11.6 per  
100, 000 population between 1983 and 2007, in male and female respectively. As to the total 
trend, the condition in Shanghai resembles these of USA and UK.
The reasons for the rise in thyroid cancer incidence are not completely understood and it 
remains unclear whether there has been a true increase in the incidence of the cancer, or whether  
this  is  merely  an  artifact  of  improved  screening  and  detection  of  cancer.  Recently,  some 
researchers have suggested that this increase is predominantly due to improved screening practices
—more widespread use of neck ultrasound, fine-needle aspiration (FNA) biopsy of small nodules, 
as  well  as  more  frequent  “incidentalomas”  found on nonthyroid  ultrasound or  cross-sectional 
imaging.4,15 In the present, the similar increasing trend in Shanghai with that in USA and UK 
might suggest that improved screening practices contributed to the increase of incidence of thyroid 
cancer to  some extent.  However,  due to the absence of  the incidence of  different histological  
types, it is impossible to evaluate the extent that improved screening practices can explain the 
increasing trend. 
Luc  et  al  performed  a  detailed  population-based  analysis  of  incidence  trends  in  well-
differentiated thyroid carcinoma (1973–2006) in the Surveillance Epidemiology and End Results 
(SEER)  cancer  registry,  using  weighted  least  squares  and  Joinpoint  regression  models,  and 
concluded that the improved detection did explain increased diagnoses of small thyroid cancers 
but not that of large cancers (>4 cm or >6 cm), which still more than doubled between 1973 and 
2006.16 It can be inferred that population-wide dietary, hormonal, or genetic risk factors may play 
some role in the changing incidence of thyroid cancer.17 
The  analysis  using  Joinpoint  regression  in  our  study  indicated  that  there  were  both  two 
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distinct slopes, a relative slight increase (APC=2.6%) from 1983 to 2000 and a sharply increase 
(APC=14.4%) after 2000 in male, and also a relative slight increase (APC=4.9%) from 1983 to  
2003 and a sharply increase (APC=19.9%) after 2003 in female. This sharply increase happened to 
occur in 5 and 8 years after 1995 when China fully carried out their state-sponsored program to 
iodize salts. 
Supplementation of iodine by means of salt fortification has been proved to be an effective 
method for the prevention of iodine deficiency disorders. However,  the acute increase in iodine 
intake carries risks, such as development of iodine-induced hyperthyroidism (IIH), autoimmune 
thyroiditis and Hypothyroidism.18 It has been reported that incidence of thyroid cancer increase 
after supplementation of iodine by means of salt.19-23 Shanghai is a seaside city, and has never been 
recorded case of IDD, suggesting the diet iodine in Shanghai is not absent. Thus the continuous 
supplements of  iodine may lead to side-effect. Due to the absence of the incidence of different 
histological types, it is impossible to evaluate the extent that improved screening practices can  
explain the increasing trend, or to exclude the association between supplement of iodine and the 
increasing trend. 
Besides, the future burden of thyroid cancer in Shanghai were predicted, using the average 
APC from 1983 to 2007 when developed screening technique can explain the increasing incidence 
of thyroid cancer, or using the average APC of the last slope when reasons other of developed 
screening technique attributed to the increasing incidence of thyroid cancer. It should be noted that 
thyroid cancer is never an unusual cancer, either in the present (Ranked 13 and 6 in male and 
female of all the cancers, respectively, in 200713) or in the future (See table 1).  
In brief, the study confirms the increasing incidence of thyroid cancer in Shanghai, China, in 
recent decades; and estimates the future burden of thyroid cancer in 2010, 2015 and 2020. Either 
the developed screening techniques or the environmental factor like supplement of iodine by salt 
might contribute to this speed-up increase incidence of thyroid in 5 and 8 years after China fully 
carried out their state-sponsored program to iodize salts. The predicated future burdens indicated 
that thyroid cancer is never an unusual cancer, either in the present or in the future in Shanghai,  
China.
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